Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Dr Harry H Yoon, including the following topics:
- Integration of Immune Checkpoint Inhibitors into the Management of HER2-Negative Gastroesophageal (GE) Cancers
- Introduction (0:00)
- Adjuvant immunotherapy for GE cancers (1:54)
- First-line anti-PD-1/PD-L1 antibody-based regimens for metastatic HER2-negative GE cancer (13:11)
- Future role of novel immunotherapies/checkpoint inhibitors (20:57)
- Optimal Management of HER2-Positive GE Cancers
- Selection of first-line therapy for metastatic HER2-positive GE cancer (28:37)
- Selection of second-line therapy for metastatic HER2-positive GE cancer (36:56)
- Therapeutic Options for Relapsed/Refractory GE Cancers; Novel Investigational Approaches
- Selection of second-line therapy for metastatic HER2-negative GE cancer (42:11)
- Zolbetuximab/chemotherapy as first-line therapy for claudin 18.2-positive metastatic GE cancer (43:09)
- Use of circulating tumor DNA assays for patients with GE cancers (53:37)
CME information and select publications
